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i.org/1treatment options. This analysis evaluated the effect of a monoclonal antibody to proprotein
convertase subtilisin/kexin 9, alirocumab 150 mg every 2 weeks (Q2W), on Lp(a) levels in
pooled data from 3 double-blind, randomized, placebo-controlled, phase 2 studies of 8 or
12 weeks’ duration conducted in patients with hypercholesterolemia on background lipid-
lowering therapy (NCT01266876, NCT01288469, and NCT01288443). Data were available
for 102 of 108 patients who received alirocumab 150 mg Q2W and 74 of 77 patients who
received placebo. Alirocumab resulted in a signiﬁcant reduction in Lp(a) from baseline
compared with placebo (L30.3% vs L0.3%, p <0.0001). Median percentage Lp(a)
reductions in the alirocumab group were of a similar magnitude across a range of baseline
Lp(a) levels, resulting in greater absolute reductions in Lp(a) in patients with higher
baseline levels. Regression analysis indicated that <5% of the variance in the reduction of
Lp(a) was explained by the effect of alirocumab on low-density lipoprotein cholesterol. In
conclusion, pooled data from 3 phase 2 trials demonstrate substantive reduction in Lp(a)
with alirocumab 150 mg Q2W, including patients with baseline Lp(a) >50 mg/dl.
Reductions in Lp(a) only weakly correlated with the magnitude of low-density lipoprotein
cholesterol lowering.  2014 The Authors. Published by Elsevier Inc. All rights reserved.
(Am J Cardiol 2014;114:711e715)Elevated lipoprotein(a) [Lp(a)] levels are considered to
be an independent risk factor for cardiovascular disease,
with risk continuing to increase as levels increase.1,2 The
2011 European Atherosclerosis Society/European Society of
Cardiology dyslipidemia management guidelines recom-
mend measurement of Lp(a) in high-risk patients or in those
with a family history of premature cardiovascular disease,3
and the European Atherosclerosis Society deﬁnes high-risk
Lp(a) levels as >50 mg/dl, approximately the eightieth
percentile in the Caucasian population.2 Of the widely
prescribed lipid-modifying therapies, only nicotinic acid
consistently reduces Lp(a).2 Despite the potent effect off Medicine, Université de Montreal, The ECOGENE-21
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0.1016/j.amjcard.2014.05.060statins on low-density lipoprotein cholesterol (LDL-C)
levels, in general, they show little to no effect on Lp(a)
in clinical trials.4 Alirocumab (formerly SAR236553/
REGN727), a highly speciﬁc fully human monoclonal
antibody to proprotein convertase subtilisin/kexin type 9
(PCSK9), signiﬁcantly (p <0.001) reduced LDL-C by up to
72.4% when combined with statin or other lipid-lowering
therapy in phase 2 trials and showed a trend to reduce
Lp(a), a secondary parameter, across all dosing regimens
tested.5e7 The objective of the present pooled analysis of
alirocumab 150 mg Q2W, a common dose in all phase 2
trials, was to provide, post hoc, a more robust assessment of
its effects on Lp(a) and examine the relation with baseline
levels and LDL-C reductions.
Methods
Data were pooled from 3 double-blind, randomized,
placebo-controlled, phase 2 studieswith alirocumab of 8 or 12
weeks’ duration (NCT01288443, NCT01266876, and
NCT01288469). The study designs (Supplementary Figure 1)
have been previously described.5e7 Brieﬂy, in these studies,
352 patients with heterozygous familial hypercholesterolemia
or nonfamilial forms of hypercholesterolemia and LDL-C
100 mg/dl under background statin or statin plus ezeti-
mibe 10 mg treatment were randomized to alirocumab 50 to
300mgQ2Wor every 4 weeks (n¼ 275) or placebo (n¼ 77).
One of the studies included uptitration of backgroundwww.ajconline.org
Table 1
Patient baseline characteristics (pooled randomized population)
Mean  Standard Deviation
Unless Otherwise Stated
Placebo
(n ¼ 77)
Alirocumab 150 mg
Every 2 Weeks (n ¼ 108)
Age (years) 54  9 58  10
Males, n (%) 38 (49%) 47 (44%)
White or European
American, n (%)
65 (84%) 96 (89%)
Black or African American,
n (%)
10 (13%) 12 (11%)
Other race, n (%) 2 (3%) 0
Body mass index
(kilograms per meter2)
29  5 29  5
Low-density lipoprotein
cholesterol (milligrams
per deciliter)
131  28 127  25
Total cholesterol
(milligrams per deciliter)
211  32 208  31
High-density lipoprotein
cholesterol (milligrams
per deciliter)
52  14 54  15
Non-high-density
lipoprotein cholesterol
(milligrams per deciliter)
159  31 154  31
Triglycerides, median
(interquartile range)
(milligrams per deciliter)
123 (92e174) 124 (88e169)
Apolipoprotein B*
(milligrams per deciliter)
109  23 108  24
* n ¼ 76 and n ¼ 107 patients randomized to placebo and alirocumab
150 mg Q2W, respectively, had apolipoprotein B data available at baseline.
Table 2
Baseline lipoprotein(a) levels in patients included in the pooled analysis
(pooled modiﬁed intent-to-treat population*)
Variable Placebo
(n ¼ 74)
Alirocumab 150 mg
Every 2 Weeks (n ¼ 102)
Lipoprotein(a), median
(interquartile range)
(milligrams per
deciliter)
19 (6e77) 30 (8e70)
Range, milligrams per
deciliter
2e299 2e181
Patients subdivided by baseline lipoprotein(a)
50 mg/dl, n (%) 49 (66%) 68 (67%)
>50 mg/dl, n (%) 25 (34%) 36 (35%)
* Patients with Lp(a) data available at baseline and end of treatment
(week 8/12 on-treatment value or the last available on-treatment value
carried forward).
Figure 1. Effect of alirocumab 150 mg Q2W on Lp(a) (pooled modiﬁed
intention-to-treat population). Shown are absolute changes from baseline
(A) or percentage changes from baseline (B) in Lp(a), with patients sub-
divided by baseline Lp(a) levels. *p <0.0001 versus placebo. p Values were
derived from analysis of covariance with the treatment group and study as
ﬁxed effects and baseline Lp(a) as a covariate, are provided for descriptive
purposes only, and were not adjusted for multiplicity. IQR ¼ interquartile
range; LOCF ¼ last observation carried forward.
712 The American Journal of Cardiology (www.ajconline.org)atorvastatin from 10 to 80 mg in the placebo arm and 1 of 2
alirocumab arms; in the other alirocumab arm, patients
remained at a background atorvastatin dose of 10 mg.7 This
study was included in the pooled analysis because impact of
statin uptitration on Lp(a) was expected to be low based on
previous studies.4 This analysis focuses on the dose regimen
alirocumab 150mgQ2W,whichwas common to all 3 phase 2
studies and was considered to provide consistent robust ef-
fects on LDLC5,6; this is also one of the doses being evaluated
in the alirocumab phase 3 clinical trials.In all phase 2 studies, Lp(a) levels were measured at the
same laboratory using rate immunonephelometry (Dade
Behring BNII nephelometer; Siemens Healthcare Di-
agnostics, Deerﬁeld, Illinois).5,6 Data on Lp(a) levels at
baseline and end of treatment (week 8 or 12 on-treatment
value or the last available on-treatment value carried for-
ward) from the modiﬁed intention-to-treat populations of the
3 studies were pooled, and percentage changes from base-
line for alirocumab 150 mg Q2W and placebo were
compared using analysis of covariance with the treatment
group and study as ﬁxed effects and baseline Lp(a) as a
covariate. p Values associated with these exploratory ana-
lyses are provided for descriptive purposes only and were
not adjusted for multiplicity. The relation between the per-
centage changes from baseline in Lp(a) and LDL-C was
Figure 2. Biology of Lp(a). (1) Lp(a) consists in an apo(a) covalently bound
to the apo B-100 component of an LDL-like particle. The Lp(a) proteic
backbone [apo(a) and apoB-100] is synthesized in the liver, whereas the
Lp(a) assembly is suspected to take place at the outer hepatocyte surface.
Apo(a) proteins vary in size because of a variable number of kringle IV
repeats in the LPA gene. (2) The half-life of Lp(a) in circulation is >3 days.
Although the mechanisms through which Lp(a) promotes atherosclerosis
and atherothrombosis are not clearly understood, proposed mechanisms
include inﬂammatory cell recruitment, increased Lp(a)-cholesterol entrap-
ment in the intima, transport of proatherogenic oxidized phospholipids, and
platelet activation, impairing ﬁbrinolysis by inhibition of plasminogen
activation, and enhancing coagulation by inhibition of the tissue factor
pathway inhibitor. (3) Lp(a) has been recently associated with valvular
calciﬁcation and aortic stenosis. (4) The pathways of Lp(a) clearance are
unclear. The liver seems to be importantly involved, although the contri-
bution of the LDL-receptor in this process appears to be less important than
expected. Several clearance receptors have been identiﬁed, although their
respective contributions to Lp(a) removal remain to be determined. (5) The
kidney appears to contribute to Lp(a) clearance. Peripheral tissues also
may contribute to Lp(a) removal from the plasma. Apo ¼ apolipoprotein;
LPA ¼ apolipoprotein(a) gene; PAI1 ¼ plasminogen activator inhibitor-1;
SMC ¼ smooth muscle cells; TFPI ¼ tissue factor pathway inhibitor.
Preventive Cardiology/Alirocumab Reduces Plasma Lipoprotein(a) Levels 713assessed using linear regression, and the Spearman corre-
lation coefﬁcient was calculated.
Results
Baseline characteristics (Table 1) were well balanced. All
patients were receiving background statin therapy, and 11 of
108 patients (10%) in the alirocumab group and 11 of 77
patients (14%) in the placebo group also received ezetimibe
10 mg. Baseline and on-treatment Lp(a) data were available
for 102 of the 108 patients who received alirocumab and 74
of the 77 patients who received placebo (Table 2). Thirty-six
patients (34%) treated with alirocumab and 25 patients
(33%) treated with placebo had baseline Lp(a) >50 mg/dl,
the high-risk cut point proposed by the European Athero-
sclerosis Society guidelines.2
Absolute and percentage median reductions from base-
line in Lp(a) are shown in Figure 1. The median absolute
reductions in Lp(a) from baseline were substantially greater
in patients with a higher baseline Lp(a) level (Figure 1).
Reductions in Lp(a) were only weakly correlated with the
magnitude of LDL-C lowering (Spearman correlation
coefﬁcient, 0.2236; Supplementary Figure 2). Similar results
were observed using a regression analysis comparing actualachieved LDL-C levels and percentage reduction in Lp(a)
(Supplementary Figure 2). The percentage reductions in
Lp(a) from baseline with alirocumab were consistent
between a pool of the two 12-week studies and a pool of the
2 arms receiving alirocumab in the 8-week study (28.3%
and 32.1%, respectively).
The most common treatment-emergent adverse event in
the alirocumab phase 2 trials was injection site reaction,
typically episodic and of mild intensity and short duration; 5
serious adverse events occurred in 4 patients (1.5%) who
received alirocumab.5e7Discussion
This analysis of pooled data from the phase 2 studies
with alirocumab 150 mg Q2W compared with placebo
demonstrated robust and statistically signiﬁcant (p <0.0001)
reductions in Lp(a) ofw30%. This compares favorably with
those reported with extended-release nicotinic acid 2 g/day
(w20 to 35%)8,9 and is consistent with those reported with
the PCSK9 monoclonal antibody evolocumab (18% to 32%
vs placebo).10,11 As reported for evolocumab, the absolute
(mg/dl) reductions in Lp(a) with alirocumab showed a
greater reduction in the patients considered by treatment
guidelines to have elevated Lp(a) levels.2,10,11
The effect of statins on Lp(a) has been extensively
evaluated over the past 3 decades, and in all large well-
controlled studies, there has been no or only minimal
effects.4,12 Of the widely prescribed lipid-lowering thera-
pies, only nicotinic acid 1 to 3 g/day has been shown to
consistently reduce Lp(a) levels.2 Recently, reductions in
Lp(a) of 21% to 33% have been reported with apo B syn-
thesis inhibition using mipomersen13,14 and of 15% to 17%
with microsomal triglyceride transfer protein inhibition
using lomitapide.15 However, these drugs are approved only
for rare patients with homozygous familial hypercholester-
olemia. Inhibition of cholesteryl ester transfer protein with
anacetrapib was reported to reduce Lp(a) by 17% to 24%16;
however, this drug is still in development and other cho-
lesteryl ester transfer protein inhibitors (torcetrapib and
dalcetrapib) have so far failed to demonstrate a positive
effect on cardiovascular events and be approved for use. In
addition to drug therapy, apheresis reduces high Lp(a)
levels, but its use in routine practice is also limited.2
The mechanisms by which Lp(a) is synthesized, metab-
olized, and cleared from the circulation are poorly under-
stood (Figure 2), and the mechanism by which PCSK9
monoclonal antibodies reduce Lp(a) is also unclear. Both
statins and alirocumab are believed to reduce LDL-C and
most other apo Becontaining lipoproteins by increasing the
number of low-density lipoprotein (LDL) receptors on
hepatocytes: statins through HMG-CoA inhibition17 and
alirocumab through PCSK9 blockade.18 It is generally
considered that the Lp(a) particle has poor afﬁnity for the
LDL receptor.19 One hypothesis is that the further upregu-
lation of the LDL receptor combined with the very low LDL
and apo B levels achieved with alirocumab treatment allows
for uptake of Lp(a) by LDL receptors. For example, the
mean achieved LDL-C level for the 150 mg Q2W arms in
these 3 studies ranged from 34.2 to 50.3 mg/dl, mean levels
714 The American Journal of Cardiology (www.ajconline.org)that are lower than those typically achieved in randomized
trials of statins alone (w60 to 100 mg/dl).20,21
Regression analysis conducted in this study
(Supplementary Figure 2) showed that a portion of the
observed reduction in Lp(a) was not dependent on the
magnitude of LDL-C lowering or the LDL-C level achieved.
In addition, the Justiﬁcation for the Use of Statins in Pre-
vention: an Intervention Trial Evaluating Rosuvastatin ach-
ieved LDL-C levels <50 mg/dl in 7,746 patients with no
reductions seen in Lp(a).22 These data suggest an effect of
alirocumab on Lp(a) production or fractional clearance that
may be independent of, or in addition to, the mechanism of
LDL-C lowering. The LDL receptoreindependent reduction
is supported by the recent report of a 15% to 20% decrease in
Lp(a) in 2 LDL receptorenegative patients with homozygous
familial hypercholesterolemia treated with evolocumab, who
had no associated reduction in LDL-C.23 However, 2 reports
on the effects of evolocumab on Lp(a)10,11 indicated a
stronger correlation between Lp(a) and LDL-C reductions
than what was observed in the present analysis; this
discrepancy may be due to the larger patient numbers
increasing the statistical power of the evolocumab studies.
In terms of synthesis, apo(a), one of the principal com-
ponents of Lp(a), is expressed by hepatocytes and released
into the circulation where the assembly of apo(a) and LDL
apo Becontaining particles bind to form Lp(a) particles at
the outer hepatocyte surface.24 The ability to reduce Lp(a)
by either inhibition of LDL-apo B or apo(a) synthesis
indicates the requirement of both for its formation.14,25 The
liver contributes to Lp(a) removal from the circulation,26
although, as mentioned previously, the mechanism is
unclear.19 The kidney and peripheral tissues may also play
an important role in Lp(a) clearance.27 New emerging
receptors have also been proposed, although their respective
contributions to Lp(a) clearance remain to be determined.
Such receptors include, among others, sorting receptors (such
as sortilin28), endocytic receptors (such as the syndecan-1
heparan sulfate proteoglycan29), or docking receptors. The
effect of PCSK9 inhibition on the regulation of receptors other
than the LDL receptor is still under investigation.
The present analysis did not take into consideration vari-
ations in the number of kringle IV repeats in the LPA gene
encoding apo(a), which account for w25% to 30% of the
variation in Lp(a) plasma concentrations.2,30 However, we
did not observe a relation betweenLp(a) concentration and the
response to alirocumab in terms of LDL-C lowering.
Approximately 30% of patients in this analysis had Lp(a)
>50 mg/dl at baseline. High Lp(a) levels are known to affect
LDL-C levels calculated using the Friedewald method, with
w8% of the cholesterol measured as LDL-C estimated to be
due to Lp(a) in patients with a baseline Lp(a) level of 30 to
60 mg/dl, and a corresponding ﬁgure of w20% with Lp(a)
>60 mg/dl.4 This was not taken into account for the regres-
sion analysis; to correct for the cholesterol in LDL-C, which
was due to Lp(a), previous studies have subtracted the Lp(a)
mass, multiplied by 0.3, from the LDL-C values.4Acknowledgment: Medical writing support was provided
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